Yapan Bio Private Limited specializes in process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics.

Yapan Bio Private Limited 专注于疫苗和生物制品的工艺开发、表征以及 I 期和 II 期 GMP 生产服务。

Piramal has held a stake in Yapan Bio since 2021, enabling the Company to provide a broad range of capabilities across biologics development and manufacturing.

自2021年以来，Piramal一直持有Yapan Bio的股份，使该公司能够提供涵盖生物制剂开发和制造的广泛能力。

This acquisition transforms Yapan Bio from Piramal's associate company to its subsidiary, enhancing the Company's ability to offer complex, integrated large molecule CDMO services.

此次收购使Yapan Bio从Piramal的关联公司转变为其子公司，增强了公司提供复杂、整合的大分子CDMO服务的能力。

MUMBAI, India

印度孟买

,

，

Aug. 18, 2026

2026年8月18日

/PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ('PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ('Yapan Bio'), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD.

/PRNewswire/ -- Piramal Pharma Ltd.（NSE: PPLPHARMA）（BSE: 543635）（“PPL”）已完成对Yapan Bio Private Limited（“Yapan Bio”）额外40.67%股权的收购。Yapan Bio是一家总部位于海得拉巴的合同研发生产组织（CDMO），专注于疫苗和生物制品。此次收购的总现金对价为7.6亿印度卢比（约合795万美元）。

As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL..

通过此次交易，PPL 现持有 Yapan Bio 74% 的股权，使 Yapan Bio 成为 PPL 的子公司。

Continue Reading

继续阅读

Peter DeYoung, CEO, Piramal Global Pharma

彼得·德扬，皮拉马尔全球制药公司首席执行官

Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule capabilities into its integrated service offering, enabling the Company to offer customers broader services in the space and expanding its ability to develop and scale complex biologic therapies with greater efficiency.

该收购于2026年8月18日完成，标志着PPL在扩大其生物制品领域布局的长期战略中迈出了重要一步。随着交易的完成，PPL将把该子公司先进的大分子能力全面融入其一体化服务体系，从而为客户提供更广泛的服务，并提升其以更高效方式开发和规模化生产复杂生物疗法的能力。

The subsidiary will continue to operate within the structure of Piramal Pharma Solutions (PPS), the CDMO arm of PPL..

该子公司将继续在Piramal Pharma Solutions（PPS，即PPL的合同研发生产组织部门）的架构内运营。

Yapan Bio also directly supports ADCelerate™ — PPS's fixed-price, integrated platform that streamlines Phase I ADC development from R&D to GMP in as little as 12 months. This acquisition further enhances ADCelerate™ and reinforces PPL's ability to deliver life-saving ADCs to market with speed and consistency..

Yapan Bio 还直接支持 ADCelerate™——PPS 推出的固定价格一体化平台，可将 ADC 的一期开发从研发到 GMP 生产的全流程缩短至仅 12 个月。此次收购进一步强化了 ADCelerate™ 平台，并增强了 PPL 以快速且一致的方式将挽救生命的 ADC 药物推向市场的能力。

'This strategic investment doesn't just fuel our long-term growth; it also puts Patient Centricity into action,' said Peter DeYoung, CEO, Piramal Global Pharma. 'By integrating Yapan Bio's specialized expertise into our global network, we're empowering our partners to meet a rising global demand for complex biologics and helping patients worldwide secure continued access to the therapies they need.'.

“这项战略投资不仅为我们的长期增长注入动力，还将‘以患者为中心’的理念付诸实践。”Piramal Global Pharma 首席执行官 Peter DeYoung 表示。“通过将 Yapan Bio 的专业专长融入我们的全球网络，我们正赋能合作伙伴满足全球对复杂生物制品日益增长的需求，并帮助全球患者确保持续获得他们所需的治疗方案。”

About Piramal Pharma Solutions

关于 Piramal Pharma Solutions

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.

Piramal Pharma Solutions（PPS）是一家合同开发与制造组织（CDMO），提供覆盖药物全生命周期的端到端开发与制造解决方案。我们通过遍布北美、欧洲和亚洲的全球一体化设施网络为客户提供服务。这使我们能够提供全面的服务，包括药物发现解决方案、工艺与药学开发服务、临床试验用药供应、活性药物成分（API）的商业化供应以及成品制剂。

We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's subsidiary, Yapan Bio Private Limited..

我们还提供专业服务，包括高活性原料药的开发与生产、抗体药物偶联物、无菌灌装/封口、肽类产品与服务，以及高活性固体口服药物制剂。通过 Piramal Pharma Limited 的子公司 Yapan Bio Private Limited，PPS 还提供生物制品（包括疫苗和基因疗法）的开发与生产服务。

For more information visit:

更多信息请访问：

Piramal Pharma Solutions

皮拉马尔制药解决方案

|

|

LinkedIn

领英

|

|

Facebook

脸书

|

|

X

X

About Piramal Pharma Limited

关于 Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products.

Piramal Pharma Limited（PPL，NSE: PPLPHARMA | BSE: 543635）通过其遍布全球的17个研发与生产设施以及覆盖100多个国家的全球分销网络，提供一系列差异化产品与服务。PPL旗下包括：Piramal Pharma Solutions（PPS），一家一体化的合同研发与生产组织；Piramal Critical Care（PCC），一家专注于复杂医院仿制药业务的公司；以及Piramal Consumer Healthcare业务，主营非处方消费者健康与 wellness 产品的销售。

In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market..

此外，PPL 的关联公司之一——雅培与 PPL 合资成立的艾伯维制药印度私人有限公司，已成为印度医药市场眼科治疗领域的市场领导者之一。

For more information, visit:

更多信息，请访问：

Piramal Pharma

皮拉马尔制药

|

|

LinkedIn

领英

SOURCE Piramal Pharma Solutions

来源：Piramal Pharma Solutions

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示